Stock Events

Stock Events

Adaptimmune Therapeutics 

€0.010000
157
-€0.01-41.18% Monday 14:17

Statistics

Day High
0.01
Day Low
0.01
52W High
0.232
52W Low
0.001
Volume
0
Avg. Volume
5,318
Mkt Cap
15.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-41.02%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
164.76MRevenue
-67.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 473A.STU. It's not an investment recommendation.
Realty Income
5
O
Microsoft
3
MSFT
Amazon
3
AMZN
Alphabet
3
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is involved in the development of cellular therapy products for cancer, directly competing with Adaptimmune's focus on T-cell therapy for cancer treatment.
Novartis
NVS
Mkt Cap304.1B
Novartis is a major player in the CAR-T cell therapy market with its approved products, competing with Adaptimmune's focus on similar cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap680.62M
Allogene Therapeutics is focused on the development of allogeneic CAR-T therapies, which could compete with Adaptimmune's autologous T-cell therapy approach.
Pfizer
PFE
Mkt Cap162.16B
Pfizer has a broad oncology portfolio, including investments in immunotherapies that could compete with Adaptimmune's T-cell based therapies.
Merck
MRK
Mkt Cap370.89B
Merck & Co. is heavily involved in cancer immunotherapy with its blockbuster drug Keytruda and is expanding into cellular therapies, potentially competing with Adaptimmune.

About

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
Show more...
CEO
Christopher James Hill
Employees
272
Country
United Kingdom
ISIN
US00653A1079
WKN
000A14SUX

Listings

MU
DE
473A.MU
STU
DE
473A.STU
OTC Link
US
ADAPY

0 Comments

Share your thoughts

FAQ

What is Adaptimmune Therapeutics stock price today?▼
The current price of 473A.STU is €0.01 EUR — it has decreased by -41.18% in the past 24 hours. Watch Adaptimmune Therapeutics stock price performance more closely on the chart.
What is Adaptimmune Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Adaptimmune Therapeutics stocks are traded under the ticker 473A.STU.
Is Adaptimmune Therapeutics stock price growing?▼
473A.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Adaptimmune Therapeutics has showed a -72.6% decrease.
What is Adaptimmune Therapeutics market cap?▼
Today Adaptimmune Therapeutics has the market capitalization of 15.9M
What is Adaptimmune Therapeutics revenue for the last year?▼
Adaptimmune Therapeutics revenue for the last year amounts to 164.76M EUR.
What is Adaptimmune Therapeutics net income for the last year?▼
473A.STU net income for the last year is -67.58M EUR.
How many employees does Adaptimmune Therapeutics have?▼
As of September 08, 2026, the company has 272 employees.
In which sector is Adaptimmune Therapeutics located?▼
Adaptimmune Therapeutics operates in the Health & Wellness sector.
When did Adaptimmune Therapeutics complete a stock split?▼
Adaptimmune Therapeutics has not had any recent stock splits.
Where is Adaptimmune Therapeutics headquartered?▼
Adaptimmune Therapeutics is headquartered in Abingdon, United Kingdom.